Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 6
2022 3
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ayumi kaneko (2 results)?
Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer.
Kaneko A, Kobayashi N, Miura K, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Watanabe K, Horita N, Hara Y, Kudo M, Miyazawa N, Kaneko T. Kaneko A, et al. Thorac Cancer. 2024 Apr 11. doi: 10.1111/1759-7714.15304. Online ahead of print. Thorac Cancer. 2024. PMID: 38602166 Free article.
Improved diagnostic accuracy with three lung tumor markers compared to six-marker panel.
Izawa A, Hara Y, Horita N, Muraoka S, Kaneko M, Kaneko A, Somekawa K, Hirata M, Otsu Y, Matsumoto H, Nagasawa R, Tanaka K, Kubo S, Murohashi K, Aoki A, Fujii H, Watanabe K, Kobayashi N, Miura K, Nakajima H, Kaneko T. Izawa A, et al. Among authors: kaneko a. Transl Lung Cancer Res. 2024 Mar 29;13(3):503-511. doi: 10.21037/tlcr-23-855. Epub 2024 Mar 15. Transl Lung Cancer Res. 2024. PMID: 38601457 Free PMC article.
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes.
Kobayashi N, Miura K, Kaneko A, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Kudo M, Miyazawa N, Kaneko T. Kobayashi N, et al. Among authors: kaneko a. Cancers (Basel). 2023 Oct 31;15(21):5248. doi: 10.3390/cancers15215248. Cancers (Basel). 2023. PMID: 37958421 Free PMC article.
Whole-Genome Sequencing Predicting Phenotypic Antitubercular Drug Resistance: Meta-analysis.
Tagami Y, Horita N, Kaneko M, Muraoka S, Fukuda N, Izawa A, Kaneko A, Somekawa K, Kamimaki C, Matsumoto H, Tanaka K, Murohashi K, Aoki A, Fujii H, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Tagami Y, et al. Among authors: kaneko a. J Infect Dis. 2024 May 15;229(5):1481-1492. doi: 10.1093/infdis/jiad480. J Infect Dis. 2024. PMID: 37946558
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H, Somekawa K, Horita N, Ueda S, Kaneko M, Kaneko A, Fukuda N, Izawa A, Kamimaki C, Tanaka K, Murohashi K, Fuji H, Tagami Y, Aoki A, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Matsumoto H, et al. Among authors: kaneko a. Ther Adv Med Oncol. 2023 Sep 13;15:17588359231198453. doi: 10.1177/17588359231198453. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37720498 Free PMC article. Review.
Adverse events induced by nivolumab and ipilimumab combination regimens.
Somekawa K, Horita N, Kaneko A, Tagami Y, Fukuda N, Matsumoto H, Namkoong H, Fujiwara Y, Minegishi K, Fukumoto T, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Somekawa K, et al. Among authors: kaneko a. Ther Adv Med Oncol. 2022 Feb 11;14:17588359211058393. doi: 10.1177/17588359211058393. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173819 Free PMC article.
18 results